RT Journal Article
T1 N-Terminal Pro B-Type Natriuretic Peptide's Usefulness for Paroxysmal Atrial Fibrillation Detection Among Populations Carrying Cardiovascular Risk Factors.
A1 Palà, Elena
A1 Bustamante, Alejandro
A1 Clúa-Espuny, Josep Lluis
A1 Acosta, Juan
A1 Gonzalez-Loyola, Felipe
A1 Ballesta-Ors, Juan
A1 Gill, Natalia
A1 Caballero, Andrea
A1 Pagola, Jorge
A1 Pedrote, Alonso
A1 Muñoz, Miguel Angel
A1 Montaner, Joan
K1 NT-proBNP
K1 atrial fibrillation
K1 biomarker
K1 screening
K1 stroke
AB Background: Atrial fibrillation (AF) systematic screening studies have not shown a clear usefulness in stroke prevention, as AF might present as paroxysmal and asymptomatic. This study aims to determine the usefulness of some blood-biomarkers to identify paroxysmal atrial fibrillation in the context of a screening programme. Methods: A total of 100 subjects aged 65-75 years with hypertension and diabetes were randomly selected. AF was assessed by conventional electrocardiogram (ECG) and 4 weeks monitoring with a wearable Holter device (Nuubo™). N-terminal pro B-type natriuretic peptide (NT-proBNP), apolipoprotein CIII (ApoC-III), von Willebrand factor (vWF), ADAMTS13, urokinase plasminogen activator surface receptor (uPAR), and urokinase plasminogen activator (uPA) were determined in serum/plasma samples and the levels were compared depending on AF presence and mode of detection. Results: The AF prevalence in the studied population was found to be 20%. In seven subjects, AF was only detected after 1 month of Holter monitoring (hAF group). NT-proBNP levels were higher in subjects with AF compared with subjects with no AF (p 95 pg/ml cut-off showed high sensitivity and specificity to detect AF (95%, 66.2%) or hAF (85.72%, 66.2%) and was found to be an independent predictor of AF and hAF in a logistic regression analysis. NT-proBNP correlated with AF burden (r = 0.597, p = 0.024). Conclusion: NT-proBNP was elevated in AF cases not identified by ECG; thus, it may be used as a screening biomarker in asymptomatic high-risk populations, with a promising cut-off point of 95 pg/ml that requires further validation.
SN 1664-2295
YR 2019
FD 2019-11-29
LK https://hdl.handle.net/10668/27193
UL https://hdl.handle.net/10668/27193
LA en
DS RISalud
RD Apr 8, 2025